drugset / Trial / NCT04902534
Clinical Trial of Naoqingzhiming Tablets in Healthy Chinese Subjects
RandomizedSequentialDouble-blindTreatment
Summary
A single-center, randomized, double-blind, placebo-controlled, dose escalation safety, tolerability, and pharmacokinetic phase I clinical study of Naoqingzhiming Tablets in Chinese healthy subjects.
Timeline
- Start
- 2020-08-05
- Primary completion
- 2021-05-30
- Completion
- 2021-06-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Naoqingzhiming Tablets | Unknown | 180 mg | — |
| Subject | Naoqingzhiming Tablets | Unknown | 360 mg | — |
| Subject | Naoqingzhiming Tablets | Unknown | 720 mg | — |
| Subject | Naoqingzhiming Tablets | Unknown | 1080 mg | — |
| Subject | Naoqingzhiming Tablets | Unknown | 1620 mg | — |
| Subject | Naoqingzhiming Tablets | Unknown | 2160 mg | — |
Indications
No indication recorded.